Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $17.33 Average Price Target from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have been given a consensus recommendation of “Hold” by the six brokerages that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $17.33.

YMAB has been the topic of several analyst reports. BMO Capital Markets increased their price objective on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a report on Monday, March 4th. Canaccord Genuity Group lifted their price objective on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, March 4th. Finally, HC Wainwright increased their target price on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, May 13th.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB opened at $12.03 on Monday. The business’s fifty day moving average price is $13.19 and its two-hundred day moving average price is $12.75. The firm has a market capitalization of $527.91 million, a price-to-earnings ratio of -24.55 and a beta of 0.69. Y-mAbs Therapeutics has a 52 week low of $4.60 and a 52 week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The firm had revenue of $19.93 million during the quarter, compared to analyst estimates of $22.06 million. Y-mAbs Therapeutics had a negative return on equity of 21.40% and a negative net margin of 25.64%. As a group, research analysts forecast that Y-mAbs Therapeutics will post -0.45 EPS for the current year.

Insiders Place Their Bets

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 7,351 shares of the stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total value of $95,563.00. Following the completion of the sale, the insider now directly owns 232,681 shares in the company, valued at $3,024,853. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Bo Kruse sold 31,371 shares of the business’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $12.07, for a total value of $378,647.97. Following the sale, the chief financial officer now directly owns 210,877 shares of the company’s stock, valued at approximately $2,545,285.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Thomas Gad sold 7,351 shares of the company’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total transaction of $95,563.00. Following the completion of the transaction, the insider now directly owns 232,681 shares of the company’s stock, valued at $3,024,853. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 99,444 shares of company stock worth $1,203,925. Corporate insiders own 21.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of YMAB. Acadian Asset Management LLC lifted its stake in Y-mAbs Therapeutics by 24.0% in the 3rd quarter. Acadian Asset Management LLC now owns 811,261 shares of the company’s stock valued at $4,420,000 after acquiring an additional 157,173 shares in the last quarter. GSA Capital Partners LLP grew its position in Y-mAbs Therapeutics by 208.3% in the third quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock valued at $748,000 after purchasing an additional 92,765 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in Y-mAbs Therapeutics during the 4th quarter worth about $562,000. Trexquant Investment LP lifted its position in Y-mAbs Therapeutics by 417.5% during the 3rd quarter. Trexquant Investment LP now owns 76,585 shares of the company’s stock worth $417,000 after buying an additional 61,785 shares in the last quarter. Finally, Los Angeles Capital Management LLC boosted its stake in shares of Y-mAbs Therapeutics by 17.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock worth $2,432,000 after buying an additional 52,610 shares during the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.